详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Nanomedicine in Immunotherapy for Non-Small Cell Lung Cancer: Applications and Perspectives

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Division of Thoracic Tumor Multimodality Treatment, Department of Radiation Oncology, Department of Radiology, Huaxi MR Research Center (HMRRC), Institution of Radiology and Medical Imaging, Cancer Center, Breast Center, Institute of Breast Health Medicine, Laboratory of Clinical Cell Therapy, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China. [2]Functional and Molecular Imaging Key Laboratory of Sichuan Province, Research Unit of Psychoradiology, Chinese Academy of Medical Sciences, Chengdu, 610041, China.

出处：

DOI：

关键词： immunotherapy nanomedicines non-small cell lung cancer

摘要：

Non-small cell lung cancer (NSCLC) has a strikingly high incidence rate globally. Although immunotherapy brings a great breakthrough in its clinical treatment of NSCLC, significant challenges still need to be overcome. The development of novel multi-functional nanomedicines in the realm of tumor immunotherapy offers promising opportunities for NSCLC patients, as nanomedicines exhibit significant advantages, including specific targeting of tumor cells, improved drug bioavailability, reduced systemic toxicity, and overcoming of immune resistance. In this review, the core features and current clinical status of strategies for NSCLC immunotherapy including immune checkpoint blockade, antibody-drug conjugates, cell engagers, adoptive cells, and cancer vaccines, are surveyed. Particular emphasis is placed on the recent development of nanomedicines that boost these strategies. Nanomedicine can provide novel perspectives for NSCLC immunotherapy.© 2025 Wiley‐VCH GmbH.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2025]版：

无

最新[2023]版：

大类 | 2 区材料科学

小类 | 2 区物理化学 2 区材料科学：综合 3 区纳米科技

第一作者：

第一作者机构： [1]Division of Thoracic Tumor Multimodality Treatment, Department of Radiation Oncology, Department of Radiology, Huaxi MR Research Center (HMRRC), Institution of Radiology and Medical Imaging, Cancer Center, Breast Center, Institute of Breast Health Medicine, Laboratory of Clinical Cell Therapy, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.

通讯作者：

通讯机构： [1]Division of Thoracic Tumor Multimodality Treatment, Department of Radiation Oncology, Department of Radiology, Huaxi MR Research Center (HMRRC), Institution of Radiology and Medical Imaging, Cancer Center, Breast Center, Institute of Breast Health Medicine, Laboratory of Clinical Cell Therapy, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China. [2]Functional and Molecular Imaging Key Laboratory of Sichuan Province, Research Unit of Psychoradiology, Chinese Academy of Medical Sciences, Chengdu, 610041, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer [2]Perioperative immunotherapy for patients with EGFR mutant non-small cell lung cancer: Unexpected potential benefits [3]Current status and progress of PD-L1 detection: guiding immunotherapy for non-small cell lung cancer [4]VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment [5]The Effect of immunotherapy on oligometastatic non-small cell lung cancer patients by sites of metastasis [6]Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancer [7]International expert consensus on immunotherapy for early-stage non-small cell lung cancer [8]127例非小细胞肺癌免疫治疗不良反应分析 [9]Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer [10]非小细胞肺癌围手术期免疫治疗相关不良反应管理的临床诊疗建议